The VEGA Knee System is indicated for use in reconstruction of the diseased knee joint caused by osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, the need to revise failed arthroplasties or osteotomies where pain. deformity or dysfunction persist, and for patients suffering from correctable valgus or varus deformity and moderate flexion contracture.

Posterior Stabilized (PS) components are also for absent or non-functioning posterior cruciate ligament and severe anteroposterior instability of the knee ioint.

The VEGA Knee System is designed for use with bone cement.

Device Description

The VEGA Knee System is a semi-constrained cemented prosthesis with a Posterior Stabilization (PS) design. The femoral component, tibial plateau and extension stem are manufactured from Cobalt Chromium Molybdenum alloy (CoCrMo) with a Zirconium nitride (ZrN) coating. The tibial "gliding surfaces" (inserts) and patella are manufactured from Ultra High Molecular Weight Polyethylene (UHMWPE) and the tibial plug is made of PEEK. The system is made up of numerous components available in various sizes. The VEGA Knee System is compatible with Aesculap Columbus cruciate retaining/posterior stabilizing tibial plateau and augments (CRA/PSA). All components are sterile and for single use only.

AI/ML Overview

Here's an analysis of the provided FDA 510(k) summary for the VEGA Knee System, focusing on the acceptance criteria and the study that proves the device meets those criteria:

Acceptance Criteria and Device Performance for VEGA Knee System (K140452)

1. Table of Acceptance Criteria and Reported Device Performance

Acceptance Criteria Category	Specific Criteria	Performed Test/Analysis	Reported Device Performance	Outcome
Cross-Compatibility	Acceptable geometrical fit between Aesculap Columbus CRA/PSA tibial plateaus and augments with Aesculap's VEGA Knee System gliding surfaces.	Geometrical worse-case comparison	Demonstrated acceptable criteria.	Met
Risk Assessment	No new risks associated with the optional use of Columbus CRA/PSA components with the VEGA Knee System.	Analysis of the geometrical comparison results.	Showed that there are no new risks associated with the optional use Columbus CRA/PSA.	Met

2. Sample Size Used for the Test Set and Data Provenance

This submission (K140452) is for a line extension, specifically the addition of optional compatible Aesculap Columbus CRA/PSA tibial plateau and augments to the existing VEGA Knee System.

Sample Size for Test Set: Not applicable in the traditional sense of a clinical or in-vitro study with a specific number of units. The assessment was a geometrical worse-case comparison, which would involve analyzing the designs and dimensions of the components rather than testing a "sample size" of physical devices.
Data Provenance: The data is based on the design specifications and geometrical properties of the existing VEGA Knee System (cleared under K101281 and K121879) and the Columbus CRA/PSA components (previously cleared in 510(K) K053390, K071220 and K120955). This is considered retrospective in the sense that it relies on previously designed and cleared components rather than newly generated test data from a prospective study. The country of origin is not explicitly stated for the designs, but the company is US-based.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of Experts

Number of Experts: Not specified.
Qualifications of Experts: Not specified. Given the nature of the "geometrical worse-case comparison," these would likely be engineering experts with expertise in orthopedic implant design, tolerancing, and biomechanics.

4. Adjudication Method for the Test Set

Adjudication Method: Not applicable. The "study" was a geometrical comparison, not a clinical trial requiring adjudication of patient outcomes or expert consensus on clinical findings.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

MRMC Study: No, an MRMC comparative effectiveness study was not done. This type of study is relevant for diagnostic imaging devices where human readers interpret results, which is not applicable to an orthopedic implant line extension.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

Standalone Performance Study: No, a standalone algorithm performance study was not done. This type of study is relevant for AI/ML algorithms, which is not applicable to this physical implant device.

7. The Type of Ground Truth Used

Type of Ground Truth: The ground truth for this submission is based on engineering design principles, dimensional compatibility, and risk analysis methodologies. The "truth" is whether the combined components fit together without creating new risks or compromising the function of the knee system. This is an engineering/design-based ground truth.

8. The Sample Size for the Training Set

Sample Size for Training Set: Not applicable. This submission does not involve an AI/ML algorithm that requires a training set. The "fundamental scientific technology and materials" for the VEGA system are established.

9. How the Ground Truth for the Training Set Was Established

Ground Truth for Training Set Establishment: Not applicable, as there is no training set for this device. The underlying design principles and performance of the predicate devices (VEGA and Columbus components) were established through their respective 510(k) clearances, which would have involved various mechanical testing, biocompatibility, and design verification activities.

Summary

{0}------------------------------------------------

K140452

Page 1 of 2

B. 510(K) SUMMARY OF SAFETY AND EFFECTIVENESS

VEGA Knee System February 20, 2014

COMPANY:	Aesculap® Implant Systems, LLC3773 Corporate ParkwayCenter Valley, PA 18034
ESTABLISHMENT
REGISTRATION NUMBER:	3005673311

CONTACT:	Julie Tom Wing
	610-984-9147 (phone)
	610-791-6882 (fax)
	Julie.TomWing@aesculap.com

DEVICE

TRADE NAME:	VEGA Knee System
COMMON NAME:	Total Knee System
DEVICE CLASS:	CLASS II
PRODUCT CODE:	JWH
REGULATION NUMBER:	888.3560
CLASSIFICATION NAME:	Knee Joint Patellofemorotibial Polymer/Metal/PolymerSemi constrained Cemented Prosthesis

SUBSTANTIAL EQUIVALENCE

Aesculap Implant Systems, LLC believes that the optional use of compatible Columbus CRA/PSA tibial plateaus and augments (K053390; K071220 and K120955) are a line extension to Aesculap's VEGA Knee System (K101281 and K121879). This line extension remains substantially equivalent to the currently marketed Aesculap Implant Systems VEGA Knee System.

DEVICE DESCRIPTION

{1}------------------------------------------------

K140452 Page 2 of 2

INDICATIONS FOR USE

Posterior Stabilized (PS) components are also for absent or non-functioning posterior cruciate ligament and severe anteroposterior instability of the knee ioint.

The VEGA Knee System is designed for use with bone cement.

TECHNOLOGICAL CHARACTERISTICS (Compared to the Predicate)

The VEGA Knee System was cleared under K101281 and K121879. The fundamental scientific technology and materials for the VEGA system remain the same. The only difference is the addition of optional compatible Aesculap Columbus cruciate retaining/posterior stabilizing (CRA/PSA) tibial plateau and wedges previously cleared in 510(K) K053390, K071220 and K120955.

PERFORMANCE DATA

As a result of the risk analysis, a geometrical worse case comparison was used to determine cross compatibility of Aesculap Columbus CRA/PSA tibial plateau with Aesculap's VEGA Knee System gliding surfaces. Results of the geometrical analysis demonstrated acceptable criteria and showed that there are no new risks associated with the optional use Columbus CRA/PSA .

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird symbol, with three curved lines representing its wings or body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the bird symbol.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

March 25, 2014

Aesculap Implant Systems Ms. Julie Tom Wing Regulatory Affairs Specialist 3773 Corporate Parkway Center Valley, Pennsylvania 18034

Re: K140452 Trade/Device Name: Vega Knee System Regulation Number: 21 CFR 888.3560 Regulation Name: Knee joint patellofemorotibial polymer/metal/polymer semiconstrained cemented prosthesis. Regulatory Class: Class II Product Code: JWH Dated: February 21, 2014 Received: February 24, 2014

Dear Ms. Julie Tom Wing,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act that + D7 I has hatutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in

{3}------------------------------------------------

Page 2 - Ms. Julie Tom Wing

the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely vours.

Lori A. Wigqins

for Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

K140452

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement on last page.

510(k) Number (if known) K140452

Device Name VEGA Knee System

Indications for Use (Describe)

The VEGA Knee System is indicated for use in reconstruction of the joint caused by ostearthrilis, theumatoid arthris, post-traumatic arthritis, the need to revise failed arthroplastics where pain, deformity or dysfunction persist and for paticats suffering from correctable valgus or varus deformity and moderate flexion contracture.

Posterior Stabilized (PS) components are also for absent or non-finctioning posterior cruciate ligament and severe anteroposterior instability of the knee joint.

The VEGA Knee System is designed for use with bone coment.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

[] Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED,

FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

Casey L. Hanley, Ph.D

Division of Orthopedic Devices

FORM FDA 3881 (1/14)	Page 1 of 2
----------------------	-------------

{5}------------------------------------------------

This section applies only to requirements of the Paperwork Reduction Act of 1995.

"DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW."

The burden time for this collection of Information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gether and maintain the data needed and complete and review the collection of Information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Regulation Number and Section

§ 888.3560 Knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis.

(a)
Identification. A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027).(b)
Classification. Class II.